Alpha 2.0
Login Register
» Articles » PMID: 19363331

Etravirine-raltegravir, a Marked Interaction in HIV-1-infected Patients: About Four Cases

Overview
Journal AIDS
Specialty Infectious Diseases
Date 2009 Apr 14
PMID 19363331
Citations 8
Authors
Amelie Menard
Caroline Solas
Saadia Mokthari
Sylvie Bregigeon
Marie-Pierre Drogoul
Catherine Tamalet
Bruno Lacarelle
Isabelle Poizot Martin
Affiliations
Soon will be listed here.
Citing Articles

Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study.

Cummins N, Rizza S, Litzow M, Hua S, Lee G, Einkauf K PLoS Med. 2017; 14(11):e1002461.

PMID: 29182633 PMC: 5705162. DOI: 10.1371/journal.pmed.1002461.

Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics.

Larson K, King J, Acosta E Adolesc Health Med Ther. 2014; 4:79-87.

PMID: 24600298 PMC: 3912854. DOI: 10.2147/AHMT.S29462.

Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management.

Rathbun R, Liedtke M Pharmaceutics. 2013; 3(4):745-81.

PMID: 24309307 PMC: 3857057. DOI: 10.3390/pharmaceutics3040745.

Effects of etravirine on the pharmacokinetics of the integrase inhibitor S/GSK1265744.

Ford S, Gould E, Chen S, Lou Y, Dumont E, Spreen W Antimicrob Agents Chemother. 2012; 57(1):277-80.

PMID: 23114768 PMC: 3535890. DOI: 10.1128/AAC.01685-12.

Clinical Use of Inhibitors of HIV-1 Integration: Problems and Prospects.

Korolev S, Agapkina Y, Gottikh M Acta Naturae. 2012; 3(3):12-28.

PMID: 22649690 PMC: 3347602.